Summit Therapeutics SMMT Balance Sheet Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $8.24M+7.2% | $16.37M+0.6% | $4.87M-60.5% | $4.27M-72.8% | $7.68M+83.3% | ||
| $492.22M+229% | $488.18M+58.8% | $0-100% | $0-100% | $149.79M+57.0% | ||
| $616.6M+66.3% | $720.3M+70.0% | $246.47M-49.7% | $309.24M-5.9% | $370.75M+127% | ||
| $1.66M+155% | $1.06M+317% | $810K+206% | $690K+209% | $652K+260% | ||
| $1.97M+2.2% | $2M+7.3% | $2M+0.4% | $2.04M+8.5% | $1.92M+2.6% | ||
| $647.86M+68.8% | $751.18M+72.5% | $261.73M-48.0% | $324.04M-5.2% | $383.82M+117% | ||
| $27.55M+452% | $20.29M+338% | $22.25M+584% | $22.98M+588% | $4.99M-21.6% | ||
| $83.27M+139% | $72.99M+74.9% | $64.93M+10.0% | $60.33M-57.0% | $34.88M+48.8% | ||
| $101.92M+158% | $92.32M+97.2% | $69.47M+7.0% | $64.6M-56.0% | $39.49M-70.2% | ||
| 1B0.0% | 1B+13,457% | 1B0.0% | 1B0.0% | 1B0.0% | ||
| -$2.48B-94.4% | -$2.29B-88.9% | -$2.07B-79.9% | -$1.84B-68.0% | -$1.28B-23.2% | ||
| $545.93M+58.5% | $658.86M+69.5% | $192.26M-56.1% | $259.44M+33.0% | $344.33M+679% | ||
| $647.86M+68.8% | $751.18M+72.5% | $261.73M-48.0% | $324.04M-5.2% | $383.82M+117% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Summit Therapeutics's total assets?
- Summit Therapeutics (SMMT) holds $647.9M in total assets, up 68.8% year over year.
- How much debt does Summit Therapeutics have?
- Summit Therapeutics carries $20.0M in total debt against $545.9M of shareholders' equity, a debt-to-equity ratio of 0.04.
- How much cash does Summit Therapeutics have?
- Summit Therapeutics holds $8.2M in cash and equivalents.
- Can Summit Therapeutics cover its short-term obligations?
- Its current ratio is 7.41 — current assets exceed current liabilities.
- Where does Summit Therapeutics's balance sheet data come from?
- Every line is extracted from Summit Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.